Literature DB >> 9301989

Antibiotic MICs and short time-killing against Helicobacter pylori: therapeutic potential of kanamycin.

Y Irie1, K Tateda, T Matsumoto, S Miyazaki, K Yamaguchi.   

Abstract

We compared the susceptibility of Helicobacter pylori to several antibiotics, expressed as MICs and as bactericidal effectiveness in short (3 h) time-killing studies. Of the antimicrobial agent tests, clarithromycin and amoxycillin had the lowest MIC50, 0.063 and 0.125 mg/L respectively, for 24 strains of H. pylori. Minocycline, levofloxacin and lansoprazole followed, with MIC50s of 0.5, 1, and 2 mg/L, respectively. Three-hour time-killing studies using a standard strain demonstrated a different pattern. At 4 x MIC, kanamycin, metronidazole and clarithromycin produced 4.4, 2.6 and 2.1 log decreases in viability, whereas the remaining seven antibiotics (including amoxycillin) were less bactericidal. Amoxycillin's lack of bactericidal activity during brief incubations was confirmed by examining several different clinically isolated H. pylori strains. Clarithromycin's effect, on the other hand, was strain- and concentration-dependent. Kanamycin was the most potent antibiotic in short time-killing studies, with concentrations of 1 x MIC and 4 x MIC producing a reduction of more than 2 and 4 log respectively in all ten strains. Our data suggest that the MIC of antimicrobial agents against H. pylori does not necessarily predict their activity in short time-killing studies. Furthermore, our short time-kill data suggest kanamycin as a potential therapeutic choice for H. pylori infection, even though this agent's MIC would suggest limited activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9301989     DOI: 10.1093/jac/40.2.235

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy.

Authors:  Boudewijn L M de Jonge; Amy Kutschke; Joseph V Newman; Michael T Rooney; Wei Yang; Christer Cederberg
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Gastric penetration of amoxicillin in a human Helicobacter pylori-infected xenograft model.

Authors:  A Lozniewski; A Duprez; C Renault; F Muhale; M C Conroy; M Weber; A Le Faou; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 3.  Treatment of Helicobacter pylori infection: current status and future concepts.

Authors:  Jyh-Chin Yang; Chien-Wei Lu; Chun-Jung Lin
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

4.  Interactions of 2,6-substituted purines with purine nucleoside phosphorylase from Helicobacter pylori in solution and in the crystal, and the effects of these compounds on cell cultures of this bacterium.

Authors:  Marta Narczyk; Marta Ilona Wojtyś; Ivana Leščić Ašler; Biserka Žinić; Marija Luić; Elżbieta Katarzyna Jagusztyn-Krynicka; Zoran Štefanić; Agnieszka Bzowska
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.